Mucosal immunization: A realistic alternative

Human Vaccines

Volumn 6, Issue 12, 2010, Pages 978-1006

  Otczyk, Diana C ^a,b   Cripps, Allan W ^b  

^a GRIFFITH UNIVERSITY   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

Cholera; COPD; Diarrhoeal disease; ETEC; Influenza; Mucosal immunity; Parainfluenza; Poliovirus; Respiratory disease; Rotavirus; RSV; Shigellosis; Typhoid; Vaccination; Vaccine delivery; WHO

Indexed keywords

BCG VACCINE; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR9; CHOLERA GARDE; CHOLERA TOXIN B SUBUNIT; CHOLERA VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INACTIVATED VACCINE; INFLUENZA VACCINE; INTEGRIN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; L SELECTIN; LECTIN; LIVE VACCINE; MUCORICE; NANOCARRIER; ORC VAX; POLIOMYELITIS VACCINE; RECOMBINANT VACCINE; ROTAVIRUS VACCINE; TRANSGENIC PLANT VACCINE; TYPHOID VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VASCULAR CELL ADHESION MOLECULE 1; VIROSOME; VIRULENCE FACTOR; YELLOW FEVER VACCINE;

ADENOVIRUS; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; BACTERIAL STRAIN; BIOTECHNOLOGY; BRONCHUS ASSOCIATED LYMPHOID TISSUE; CAUSE OF DEATH; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHICKENPOX; CHLAMYDIA; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CLOSTRIDIUM THERMOCELLUM; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DIARRHEA; DIPHTHERIA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSPOT ASSAY; ESCHERICHIA COLI; GASTROENTERITIS; GENE DELETION; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS A; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; INFLUENZA; INJECTION; INNATE IMMUNITY; INOCULATION; INTESTINE LYMPHATIC TISSUE; LYMPHOCYTE MIGRATION; LYMPHOID TISSUE; MEASLES; MEASLES VIRUS; MEMORY CELL; MENINGITIS; MOLECULAR INTERACTION; MORAXELLA CATARRHALIS; MORTALITY; MUCOSA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MUCOSAL IMMUNITY; MUCOSAL IMMUNIZATION; MUMPS; MYCOBACTERIUM TUBERCULOSIS; MYCOPLASMA PNEUMONIAE; NASAL DELIVERY SYSTEM; NASOPHARYNX ASSOCIATED LYMPHOID TISSUE; NEISSERIA GONORRHOEAE; OTITIS MEDIA; PARAINFLUENZA VIRUS; PERTUSSIS; PEYER PATCH; PHYSIOLOGY; POLIOMYELITIS; PSEUDOMONAS AERUGINOSA; PULMONARY DELIVERY SYSTEM; RECTAL DELIVERY SYSTEM; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; ROTAVIRUS; RUBELLA; SAFETY; SALMONELLA ENTERICA; SEROTYPE; SEXUALLY TRANSMITTED DISEASE; SHELF LIFE; SHIGELLA; STREPTOCOCCUS PNEUMONIAE; TARGET CELL; TH1 CELL; TH2 CELL; TRANSGENIC PLANT; TUBERCULOSIS; URINARY TRACT INFECTION; VACCINATION; VACCINE PRODUCTION; VAGINAL DELIVERY SYSTEM; VIBRIO CHOLERAE; VIRUS LIKE AGENT; VIRUS STRAIN;

ADMINISTRATION, MUCOSAL; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION; VACCINES;

EID: 78751657626     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.12.13142     Document Type: Review

References (277)

1. rd ed. Geneva, World Health Organisation 2009.
2. Lehner T, Bergmeier L, Wang Y, Tao L, Mitchell E. A rational basis for mucosal vaccination against HIV infection. Immunol Rev 1999; 170:183-96.
3. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994; 271:698-702.
4. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993; 22:1154-8.
5. Orege PA, Fine PE, Lucas SB, Obura M, Okelo C, Okuku P. Case-control study of BCG vaccination as a risk factor for leprosy and tuberculosis in western Kenya. Int J Lepr Other Mycobact Dis 1993; 61:542-9.
6. Nir Y, Paz A, Sabo E, Potasman I. Fear of injections in young adults: prevalence and associations. Am J Trop Med Hyg 2003; 68:341-4.
7. Giudice EL, Campbell JD. Needle-free vaccine delivery. Adv Drug Deliv Rev 2006; 58:68-89.
8. World Health Organization. Safety of injections: Global Facts & Figures. Geneva 2004.
9. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 2007; 25:5467-84.
10. Macpherson AJ, McCoy KD, Johansen FE, Brandtzaeg P. The immune geography of IgA induction and function. Mucosal Immunol 2008; 1:11-22.
11. Pabst R, Russell MW, Brandtzaeg P. Tissue distribution of lymphocytes and plasma cells and the role of the gut. Trends Immunol 2008; 29:206-8.
12. Brandtzaeg P, Kiyono H, Pabst R, Russell MW. Terminology: nomenclature of mucosa-associated lymphoid tissue. Mucosal Immunol 2008; 1:31-7.
13. Brandtzaeg P, Pabst R. Let's go mucosal: communication on slippery ground. Trends Immunol 2004; 25:570-7.
14. Kiyono H, Fukuyama S. NALT- versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol 2004; 4:699-710.
15. Clark MA, Jepson MA, Hirst BH. Exploiting M cells for drug and vaccine delivery. Adv Drug Deliv Rev 2001; 50:81-106.
16. Neutra MR, Frey A, Kraehenbuhl JP. Epithelial M cells: gateways for mucosal infection and immunization. Cell 1996; 86:345-8.
17. Jang MH, Kweon MN, Iwatani K, Yamamoto M, Terahara K, Sasakawa C, et al. Intestinal villous M cells: an antigen entry site in the mucosal epithelium. Proc Natl Acad Sci USA 2004; 101:6110-5.
18. Rescigno M, Urbano M, Valzasina B, Francolini M, Rotta G, Bonasio R, et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2001; 2:361-7.
19. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006; 6:148-58.
20. Shreedhar VK, Kelsall BL, Neutra MR. Cholera toxin induces migration of dendritic cells from the sub-epithelial dome region to T- and B-cell areas of Peyer's patches. Infect Immun 2003; 71:504-9.
21. Iwasaki A, Kelsall BL. Unique functions of CD11b+, CD8 alpha+ and double-negative Peyer's patch dendritic cells. J Immunol 2001; 166:4884-90.
22. Coffman RL, Lebman DA, Shrader B. Transforming growth factor beta specifically enhances IgA production by lipopolysaccharide-stimulated murine B lymphocytes. J Exp Med 1989; 170:1039-44.
23. Fayette J, Dubois B, Vandenabeele S, Bridon JM, Vanbervliet B, Durand I, et al. Human dendritic cells skew isotype switching of CD40-activated naive B cells towards IgA1 and IgA2. J Exp Med 1997; 185:1909-18.
24. Stavnezer J. Immunoglobulin class switching. Curr Opin Immunol 1996; 8:199-205.
25. Shikina T, Hiroi T, Iwatani K, Jang MH, Fukuyama S, Tamura M, et al. IgA class switch occurs in the organized nasopharynx- and gut-associated lymphoid tissue, but not in the diffuse lamina propria of airways and gut. J Immunol 2004; 172:6259-64.
26. McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific memory B cell development. Annu Rev Immunol 2005; 23:487-513.
27. Sato A, Hashiguchi M, Toda E, Iwasaki A, Hachimura S, Kaminogawa S. CD11b+ Peyer's patch dendritic cells secrete IL-6 and induce IgA secretion from naive B cells. J Immunol 2003; 171:3684-90.
28. Tezuka H, Abe Y, Iwata M, Takeuchi H, Ishikawa H, Matsushita M, et al. Regulation of IgA production by naturally occurring TNF/iNOS-producing dendritic cells. Nature 2007; 448:929-33.
29. Uematsu S, Fujimoto K, Jang MH, Yang BG, Jung YJ, Nishiyama M, et al. Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nat Immunol 2008; 9:769-76.
30. He B, Xu W, Santini PA, Polydorides AD, Chiu A, Estrella J, et al. Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity 2007; 26:812-26.
31. McGhee JR, Fujihashi K, Beagley KW, Kiyono H. Role of interleukin-6 in human and mouse mucosal IgA plasma cell responses. Immunol Res 1991; 10:418-22.
32. Matsumoto R, Matsumoto M, Mita S, Hitoshi Y, Ando M, Araki S, et al. Interleukin-5 induces maturation but not class switching of surface IgA-positive B cells into IgA-secreting cells. Immunology 1989; 66:32-8.
33. Kunkel EJ, Butcher EC. Plasma-cell homing. Nat Rev Immunol 2003; 3:822-9.
34. Campbell DJ, Debes GF, Johnston B, Wilson E, Butcher EC. Targeting T cell responses by selective chemokine receptor expression. Semin Immunol 2003; 15:277-86.
35. Morteau O, Gerard C, Lu B, Ghiran S, Rits M, Fujiwara Y, et al. An indispensable role for the chemokine receptor CCR10 in IgA antibody-secreting cell accumulation. J Immunol 2008; 181:6309-15.
36. Lazarus NH, Kunkel EJ, Johnston B, Wilson E, Youngman KR, Butcher EC. A common mucosal chemokine (mucosae-associated epithelial chemokine/ CCL28) selectively attracts IgA plasmablasts. J Immunol 2003; 170:3799-805.
37. Bargatze RF, Jutila MA, Butcher EC. Distinct roles of L-selectin and integrins alpha4beta7 and LFA-1 in lymphocyte homing to Peyer's patch-HEV in situ: the multistep model confirmed and refined. Immunity 1995; 3:99-108.
38. Hamann A, Andrew DP, Jablonski-Westrich D, Holzmann B, Butcher EC. Role of alpha 4-integrins in lymphocyte homing to mucosal tissues in vivo. J Immunol 1994; 152:3282-93.
39. Kantele A, Arvilommi H, Iikkanen K, Savilahti E, Makela HP, Herzog C, et al. Unique characteristics of the intestinal immune system as an inductive site after antigen reencounter. J Infect Dis 2005; 191:312-7.
40. Youngman KR, Franco MA, Kuklin NA, Rott LS, Butcher EC, Greenberg HB. Correlation of tissue distribution, developmental phenotype and intestinal homing receptor expression of antigen-specific B cells during the murine anti-rotavirus immune response. J Immunol 2002; 168:2173-81.
41. Kantele A, Westerholm M, Kantele JM, Makela PH, Savilahti E. Homing potentials of circulating antibodysecreting cells after administration of oral or parenteral protein or polysaccharide vaccine in humans. Vaccine 1999; 17:229-36.
42. Pabst O, Ohl L, Wendland M, Wurbel MA, Kremmer E, Malissen B, et al. Chemokine receptor CCR9 contributes to the localization of plasma cells to the small intestine. J Exp Med 2004; 199:411-6.
43. Papadakis KA, Prehn J, Nelson V, Cheng L, Binder SW, Ponath PD, et al. The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. J Immunol 2000; 165:5069-76.
44. Gorfu G, Rivera-Nieves J, Ley K. Role of beta7 integrins in intestinal lymphocyte homing and retention. Curr Mol Med 2009; 9:836-50.
45. Svensson M, Marsal J, Ericsson A, Carramolino L, Broden T, Marquez G, et al. CCL25 mediates the localization of recently activated CD8alphabeta(+) lymphocytes to the small-intestinal mucosa. J Clin Invest 2002; 110:1113-21.
46. Miles A, Liaskou E, Eksteen B, Lalor PF, Adams DH. CCL25 and CCL28 promote alpha4 beta7-integrindependent adhesion of lymphocytes to MAdCAM-1 under shear flow. Am J Physiol Gastrointest Liver Physiol 2008; 294:1257-67.
47. Mora JR, Iwata M, Eksteen B, Song SY, Junt T, Senman B, et al. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science 2006; 314:1157-60.
48. Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song SY. Retinoic acid imprints gut-homing specificity on T cells. Immunity 2004; 21:527-38.
49. Campbell JJ, Brightling CE, Symon FA, Qin S, Murphy KE, Hodge M, et al. Expression of chemokine receptors by lung T cells from normal and asthmatic subjects. J Immunol 2001; 166:2842-8.
50. Xu B, Wagner N, Pham LN, Magno V, Shan Z, Butcher EC, et al. Lymphocyte homing to bronchusassociated lymphoid tissue (BALT) is mediated by L-selectin/PNAd, alpha4beta1 integrin/VCAM-1 and LFA-1 adhesion pathways. J Exp Med 2003; 197:1255-67.
51. Kantele AM, Palkola NV, Arvilommi HS, Kantele JM. Distinctive homing profile of pathogen-specific activated lymphocytes in human urinary tract infection. Clin Immunol 2008; 128:427-34.
52. Goodsell A, Zhou F, Gupta S, Singh M, Malyala P, Kazzaz J, et al. Beta7-integrin-independent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery. Immunology 2008; 123:378-89.
53. Kunisawa J, Fukuyama S, Kiyono H. Mucosa-associated lymphoid tissues in the aerodigestive tract: their shared and divergent traits and their importance to the orchestration of the mucosal immune system. Curr Mol Med 2005; 5:557-72.
54. Johansen FE, Baekkevold ES, Carlsen HS, Farstad IN, Soler D, Brandtzaeg P. Regional induction of adhesion molecules and chemokine receptors explains disparate homing of human B cells to systemic and mucosal effector sites: dispersion from tonsils. Blood 2005; 106:593-600.
55. Qimron U, Paul L, Bar-Haim E, Bloushtain N, Eisenbach L, Staats HF, et al. Non-replicating mucosal and systemic vaccines: quantitative and qualitative differences in the Ag-specific CD8(+) T cell population in different tissues. Vaccine 2004; 22:1390-4.
56. Quiding M, Nordstrom I, Kilander A, Andersson G, Hanson LA, Holmgren J, et al. Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production and evokes local immunological memory. J Clin Invest 1991; 88:143-8.
57. Eriksson K, Quiding-Jarbrink M, Osek J, Moller A, Bjork S, Holmgren J, et al. Specific-antibody-secreting cells in the rectums and genital tracts of nonhuman primates following vaccination. Infect Immun 1998; 66:5889-96.
58. Kozlowski PA, Cu-Uvin S, Neutra MR, Flanigan TP. Comparison of the oral, rectal and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun 1997; 65:1387-94.
59. Jertborn M, Nordstrom I, Kilander A, Czerkinsky C, Holmgren J. Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans. Infect Immun 2001; 69:4125-8.
60. Belyakov IM, Derby MA, Ahlers JD, Kelsall BL, Earl P, Moss B, et al. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc Natl Acad Sci USA 1998; 95:1709-14.
61. Rudin A, Riise GC, Holmgren J. Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit. Infect Immun 1999; 67:2884-90.
62. Kozlowski PA, Williams SB, Lynch RM, Flanigan TP, Patterson RR, Cu-Uvin S, et al. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal or vaginal immunization: influence of the menstrual cycle. J Immunol 2002; 169:566-74.
63. Staats HF, Montgomery SP, Palker TJ. Intranasal immunization is superior to vaginal, gastric or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. AIDS Res Hum Retroviruses 1997; 13:945-52.
64. Imaoka K, Miller CJ, Kubota M, McChesney MB, Lohman B, Yamamoto M, et al. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/ Th2 help for virus-specific immune responses in reproductive tissues. J Immunol 1998; 161:5952-8.
65. Johansson EL, Bergquist C, Edebo A, Johansson C, Svennerholm AM. Comparison of different routes of vaccination for eliciting antibody responses in the human stomach. Vaccine 2004; 22:984-90.
66. Johansson EL, Wassen L, Holmgren J, Jertborn M, Rudin A. Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect Immun 2001; 69:7481-6.
67. Gallichan WS, Rosenthal KL. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. J Infect Dis 1998; 177:1155-61.
68. Mestecky J, Bienenstock J, McGhee JR, Lamm ME, Strober W, Cebra JJ, et al. Mucosal Immunology. St. Louis MO: LWW Publishers 2005.
69. Pang GT, Clancy RL, O'Reilly SE, Cripps AW. A novel particulate influenza vaccine induces long-term and broad-based immunity in mice after oral immunization. J Virol 1992; 66:1162-70.
70. Cripps AW, Dunkley ML, Clancy RL. Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infection in rats. Infect Immun 1994; 62:1427-36.
71. Malley R, Srivastava A, Lipsitch M, Thompson CM, Watkins C, Tzianabos A, et al. Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide. Infect Immun 2006; 74:2187-95.
72. Jomaa M, Kyd JM, Cripps AW. Mucosal immunisation with novel Streptococcus pneumoniae protein antigens enhances bacterial clearance in an acute mouse lung infection model. FEMS Immunol Med Microbiol 2005; 44:59-67.
73. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685-96.
74. Centre for Disease and Prevention. Suspension of rotavirus vaccine after reports of intussusception - United States 1999. MMWR Morb Mort Wkly Epidemiol Rec 2004; 786-9.
75. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004; 350:896-903.
76. Alexander LN, Seward JF, Santibanez TA, Pallansch MA, Kew OM, Prevots DR, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 2004; 292:1696-701.
77. Cripps AW, Gleeson M. Ontogeny of mucosal immunity and aging. In: Mestechy J, Lamm ME, McGhee JR, Bienenstock J, Mayer L, Strober W, Ed. Mucosal Immunol. St. Louis MO: LWW Publishers 2005.
78. Bogaert D, Veenhoven RH, Ramdin R, Luijendijk IH, Rijkers GT, Sanders EA, et al. Pneumococcal conjugate vaccination does not induce a persisting mucosal IgA response in children with recurrent acute otitis media. Vaccine 2005; 23:2607-13.
79. Gleeson M, Cripps AW, Clancy RL. Modifiers of the human mucosal immune system. Immunol Cell Biol 1995; 73:397-404.
80. Kantele A. Peripheral blood antibody-secreting cells in the evaluation of the immune response to an oral vaccine. J Biotechnol 1996; 44:217-24.
81. Lundgren A, Kaim J, Jertborn M. Parallel analysis of mucosally derived B- and T-cell responses to an oral typhoid vaccine using simplified methods. Vaccine 2009; 27:4529-36.
82. Ahmed T, Svennerholm AM, Al Tarique A, Sultana GN, Qadri F. Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding. Vaccine 2009; 27:1433-9.
83. Qadri F, Ahmed T, Wahed MA, Ahmed F, Bhuiyan NA, Rahman AS, et al. Suppressive effect of zinc on antibody response to cholera toxin in children given the killed, B subunit-whole cell, oral cholera vaccine. Vaccine 2004; 22:416-21.
84. Rennels MB. Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines. J Infect Dis 1996; 174:107-11.
85. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991; 13:926-39.
86. Long KZ, Rosado JL, Santos JI, Haas M, Al Mamun A, DuPont HL, et al. Associations between mucosal innate and adaptive immune responses and resolution of diarrheal pathogen infections. Infect Immun 2010; 78:1221-8.
87. Clancy RL, Cripps AW, Yeung S, Standish-White S, Pang G, Gratten H, et al. Salivary and serum antibody responses to Haemophilus influenzae infection in Papua New Guinea. P N G Med J 1987; 30:271-6.
88. Mayer L, Shao L. Therapeutic potential of oral tolerance. Nat Rev Immunol 2004; 4:407-19.
89. Boyaka PN, Tafaro A, Fischer R, Fujihashi K, Jirillo E, McGhee JR. Therapeutic manipulation of the immune system: enhancement of innate and adaptive mucosal immunity. Curr Pharm Des 2003; 9:1965-72.
90. Sun JB, Czerkinsky C, Holmgren J. Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit. Scand J Immunol 2010; 71:1-11.
91. Moldoveanu Z, Oliver F, Mestecky J, Elson CO. Oral tolerance in humans: failure to suppress an existing immune response by oral antigen administration. Ann N Y Acad Sci 2004; 1029:299-309.
92. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11:45-53.
93. Mestecky J, Moldoveanu Z, Elson CO. Immune response versus mucosal tolerance to mucosally administered antigens. Vaccine 2005; 23:1800-3.
94. Mestecky J, Nguyen H, Czerkinsky C, Kiyono H. Oral immunization: an update. Curr Opin Gastroenterol 2008; 24:713-9.
95. Mestecky J, Russell MW, Elson CO. Perspectives on mucosal vaccines: is mucosal tolerance a barrier? J Immunol 2007; 179:5633-8.
96. Sanchez J, Holmgren J. Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea. Curr Opin Immunol 2005; 17:388-98.
97. Salerno-Goncalves R, Pasetti MF, Sztein MB. Characterization of CD8(+) effector T cell responses in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine. J Immunol 2002; 169:2196-203.
98. Clancy RL, Dunkley ML. Oral non-typable Haemophilus influenzae enhances physiological mechanism of airways protection. Clin Exp Immunol 2010.
99. Moyle PM, McGeary RP, Blanchfield JT, Toth I. Mucosal immunisation: adjuvants and delivery systems. Curr Drug Deliv 2004; 1:385-96.
100. Lavelle EC, O'Hagan DT. Delivery systems and adjuvants for oral vaccines. Expert Opin Drug Deliv 2006; 3:747-62.
101. Chadwick S, Kriegel C, Amiji M. Nanotechnology solutions for mucosal immunization. Adv Drug Deliv Rev 2010; 62:394-407.
102. Kyd JM, Cripps AW. Functional differences between M cells and enterocytes in sampling luminal antigens. Vaccine 2008; 26:6221-4.
103. Lycke N. From toxin to adjuvant: basic mechanisms for the control of mucosal IgA immunity and tolerance. Immunol Lett 2005; 97:193-8.
104. Stephenson I, Zambon MC, Rudin A, Colegate A, Podda A, Bugarini R, et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 2006; 80:4962-70.
105. Kotloff KL, Sztein MB, Wasserman SS, Losonsky GA, DiLorenzo SC, Walker RI. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun 2001; 69:3581-90.
106. Lapa JA, Sincock SA, Ananthakrishnan M, Porter CK, Cassels FJ, Brinkley C, et al. Randomized clinical trial assessing the safety and immunogenicity of oral microencapsulated enterotoxigenic Escherichia coli surface antigen 6 with or without heat-labile enterotoxin with mutation R192G. Clin Vaccine Immunol 2008; 15:1222-8.
107. Ahmed T, Arifuzzaman M, Lebens M, Qadri F, Lundgren A. CD4+ T-cell responses to an oral inactivated cholera vaccine in young children in a cholera endemic country and the enhancing effect of zinc supplementation. Vaccine 2009; 28:422-9.
108. Lucas ME, Deen JL, von Seidlein L, Wang XY, Ampuero J, Puri M, et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med 2005; 352:757-67.
109. Sanchez JL, Vasquez B, Begue RE, Meza R, Castellares G, Cabezas C, et al. Protective efficacy of oral wholecell/ recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet 1994; 344:1273-6.
110. Clemens JD, Sack DA, Harris JR, Van Loon F, Chakraborty J, Ahmed F, et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 1990; 335:270-3.
111. van Loon FP, Clemens JD, Chakraborty J, Rao MR, Kay BA, Sack DA, et al. Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. Vaccine 1996; 14:162-6.
112. Lopez-Gigosos R, Garcia-Fortea P, Reina-Dona E, Plaza-Martin E. Effectiveness in prevention of travellers' diarrhoea by an oral cholera vaccine WC/rBS. Travel Med Infect Dis 2007; 5:380-4.
113. Ali M, Emch M, Yunus M, Sack D, Lopez AL, Holmgren J, et al. Vaccine Protection of Bangladeshi infants and young children against cholera: implications for vaccine deployment and person-to-person transmission. Pediatr Infect Dis J 2008; 27:33-7.
114. Shamsuzzaman S, Ahmed T, Mannoor K, Begum YA, Bardhan PK, Sack RB, et al. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses. Vaccine 2009; 27:1386-92.
115. Trach DD, Cam PD, Ke NT, Rao MR, Dinh D, Hang PV, et al. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam. Bull World Health Organ 2002; 80:2-8.
116. Thiem VD, Deen JL, von Seidlein L, Canh do G, Anh DD, Park JK, et al. Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam. Vaccine 2006; 24:4297-303.
117. Mahalanabis D, Lopez AL, Sur D, Deen J, Manna B, Kanungo S, et al. A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS One 2008; 3:2323.
118. Sur D, Lopez AL, Kanungo S, Paisley A, Manna B, Ali M, et al. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet 2009; 374:1694-702.
119. Kanungo S, Paisley A, Lopez AL, Bhattacharya M, Manna B, Kim DR, et al. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial. Vaccine 2009; 27:6887-93.
120. World Health Organization. Cholera vaccines: WHO position paper. Wkly Epidemiol Rec 2010; 13:117-28.
121. Silva AJ, Eko FO, Benitez JA. Exploiting cholera vaccines as a versatile antigen delivery platform. Biotechnol Lett 2008; 30:571-9.
122. Riedmann EM, Kyd JM, Cripps AW, Lubitz W. Bacterial ghosts as adjuvant particles. Expert Rev Vaccines 2007; 6:241-53.
123. Svennerholm AM, Steele D. Microbial-gut interactions in health and disease. Progress in enteric vaccine development. Best Pract Res Clin Gastroenterol 2004; 18:421-45.
124. Qadri F, Wenneras C, Ahmed F, Asaduzzaman M, Saha D, Albert MJ, et al. Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi adults and children. Vaccine 2000; 18:2704-12.
125. Qadri F, Ahmed T, Ahmed F, Begum YA, Sack DA, Svennerholm AM. Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6-17 months of age: dosing studies in different age groups. Vaccine 2006; 24:1726-33.
126. Boedeker EC. Vaccines for enterotoxigenic Escherichia coli: current status. Curr Opin Gastroenterol 2005; 21:15-9.
127. Savarino SJ, Hall ER, Bassily S, Wierzba TF, Youssef FG, Peruski LF Jr, et al. Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants. Pediatr Infect Dis J 2002; 21:322-30.
128. Sack DA, Shimko J, Torres O, Bourgeois AL, Francia DS, Gustafsson B, et al. Randomised, double-blind, safety and efficacy of a killed oral vaccine for entero-toxigenic E. Coli diarrhoea of travellers to Guatemala and Mexico. Vaccine 2007; 25:4392-400.
129. Tobias J, Lebens M, Bolin I, Wiklund G, Svennerholm AM. Construction of non-toxic Escherichia coli and Vibrio cholerae strains expressing high and immunogenic levels of enterotoxigenic E. coli colonization factor I fimbriae. Vaccine 2008; 26:743-52.
130. McKenzie R, Walker RI, Nabors GS, Van De Verg LL, Carpenter C, Gomes G, et al. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial. Vaccine 2006; 24:3735-45.
131. Levine MM, Kotloff KL, Barry EM, Pasetti MF, Sztein MB. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol 2007; 5:540-53.
132. Clancy R, Cripps A, Pang G, Yeung S, Murree-Allen K. The paradox of immunization against Haemophilus influenzae-related endobronchitis: protection restricted to ingestion of 'non-adjuvenated' vaccine. Adv Exp Med Biol 1987; 216:1759-64.
133. Clancy RL, Cripps AW, Gebski V. Protection against recurrent acute bronchitis after oral immunization with killed Haemophilus influenzae. Med J Aust 1990; 152:413-6.
134. Clancy RL, Cripps AW. Specific protection against acute bronchitis associated with nontypeable Haemophilus influenzae. J Infect Dis 1992; 165:194-5.
135. Lehmann D, Coakley KJ, Coakley CA, Spooner V, Montgomery JM, Michael A, et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. Am Rev Respir Dis 1991; 144:324-30.
136. Tandon MK, Gebski V. A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Aust N Z J Med 1991; 21:427-32.
137. Clancy R, Cripps A, Murree-Allen K, Yeung S, Engel M. Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet 1985; 2:1395-7.
138. Tandon MK, Phillips M, Waterer G, Dunkley M, Comans P, Clancy R. Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest 2010; 137:805-11.
139. Foxwell AR, Cripps AW, Dear KB. Haemophilus influenzae oral whole cell vaccination for preventing acute exacerbations of chronic bronchitis. Cochrane Database Syst Rev 2006; 001958.
140. Cripps AW, Peek K, Dunkley M, Vento K, Marjason JK, McIntyre ME, et al. Safety and immunogenicity of an oral inactivated whole-cell Pseudomonas aeruginosa vaccine administered to healthy human subjects. Infect Immun 2006; 74:968-74.
141. Naber KG, Cho YH, Matsumoto T, Schaeffer AJ. Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. Int J Antimicrob Agents 2009; 33:111-9.
142. World Health Organization. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Wkly Epidemiol Rec 2010; 23:213-28.
143. el-Sayed N, el-Gamal Y, Abbassy AA, Seoud I, Salama M, Kandeel A, et al. Monovalent type 1 oral poliovirus vaccine in newborns. N Engl J Med 2008; 359:1655-65.
144. Kim-Farley RJ, Rutherford G, Lichfield P, Hsu ST, Orenstein WA, Schonberger LB, et al. Outbreak of paralytic poliomyelitis, Taiwan. Lancet 1984; 2:1322-4.
145. Sutter RW, Patriarca PA, Brogan S, Malankar PG, Pallansch MA, Kew OM, et al. Outbreak of paralytic poliomyelitis in Oman: evidence for widespread transmission among fully vaccinated children. Lancet 1991; 338:715-20.
146. Robertson SE, Traverso HP, Drucker JA, Rovira EZ, Fabre-Teste B, Sow A, et al. Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine. Lancet 1988; 1:897-9.
147. Top FHJ, Dudding BA, Russell PK, Buescher EL. Control of respiratory disease in recruits with types 4 and 7 adenovirus vaccines. Am J Epidemiol 1971; 94:142-6.
148. Lyons A, Longfield J, Kuschner R, Straight T, Binn L, Seriwatana J, et al. A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults. Vaccine 2008; 26:2890-8.
149. Parashar UD, Gibson CJ, Bresse JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006; 12:304-6.
150. World Health Organization. Rotavirus vaccines: an update. Wkly Epidemiol Rec 2009; 51:533-40.
151. Gurgel RQ, Cunliffe NA, Nakagomi O, Cuevas LE. Rotavirus genotypes circulating in Brazil before national rotavirus vaccination: a review. J Clin Virol 2008; 43:1-8.
152. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005; 15:29-56.
153. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22.
154. Linhares AC, Velazquez FR, Perez-Schael I, Saez- Llorens X, Abate H, Espinoza F, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, doubleblind, placebo-controlled phase III study. Lancet 2008; 371:1181-9.
155. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33. (Pubitemid 43048948)
156. Ward RL. Rotavirus vaccines: how they work or don't work. Expert Rev Mol Med 2008; 10:5.
157. Advancing Rotavirus Vaccine Development project.
158. Clements-Mann ML, Dudas R, Hoshino Y, Nehring P, Sperber E, Wagner M, et al. Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants. Vaccine 2001; 19:4676-84.
159. Vesikari T, Karvonen AV, Majuri J, Zeng SQ, Pang XL, Kohberger R, et al. Safety, efficacy and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesushuman rotavirus reassortant tetravalent vaccines in Finnish children. J Infect Dis 2006; 194:370-6.
160. Bhandari N, Sharma P, Taneja S, Kumar T, Rongsen- Chandola T, Appaiahgari MB, et al. A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial. J Infect Dis 2009; 200:421-9.
161. Barnes GL, Lund JS, Mitchell SV, De Bruyn L, Piggford L, Smith AL, et al. Early phase II trial of human rotavirus vaccine candidate RV3. Vaccine 2002; 20:2950-6.
162. Gotuzzo E, Butron B, Seas C, Penny M, Ruiz R, Losonsky G, et al. Safety, immunogenicity and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect Immun 1993; 61:3994-7.
163. Suharyono, Simanjuntak C, Witham N, Punjabi N, Heppner DG, Losonsky G, et al. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9 year-old Indonesian children. Lancet 1992; 340:689-94.
164. Simanjuntak CH, O'Hanley P, Punjabi NH, Noriega F, Pazzaglia G, Dykstra P, et al. Safety, immunogenicity and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24- to 59 month-old Indonesian children. J Infect Dis 1993; 168:1169-76.
165. Richie EE, Punjabi NH, Sidharta YY, Peetosutan KK, Sukandar MM, Wasserman SS, et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 2000; 18:2399-410.
166. Tacket CO, Cohen MB, Wasserman SS, Losonsky G, Livio S, Kotloff K, et al. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination. Infect Immun 1999; 67:6341-5.
167. Calain P, Chaine JP, Johnson E, Hawley ML, O'Leary MJ, Oshitani H, et al. Can oral cholera vaccination play a role in controlling a cholera outbreak? Vaccine 2004; 22:2444-51.
168. Safa A, Nair GB, Kong RY. Evolution of new variants of Vibrio cholerae O1. Trends Microbiol 2010; 18:46-54.
169. Kenner JR, Coster TS, Taylor DN, Trofa AF, Barrera- Oro M, Hyman T, et al. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1. J Infect Dis 1995; 172:1126-9.
170. Taylor DN, Killeen KP, Hack DC, Kenner JR, Coster TS, Beattie DT, et al. Development of a live, oral, attenuated vaccine against El Tor cholera. J Infect Dis 1994; 170:1518-23.
171. Sack DA, Sack RB, Shimko J, Gomes G, O'Sullivan D, Metcalfe K, et al. Evaluation of Peru-15, a new live oral vaccine for cholera, in volunteers. J Infect Dis 1997; 176:201-5. (Pubitemid 27272870)
172. Cohen MB, Giannella RA, Bean J, Taylor DN, Parker S, Hoeper A, et al. Randomized, controlled human challenge study of the safety, immunogenicity and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. Infect Immun 2002; 70:1965-70. (Pubitemid 34242197)
173. Qadri F, Chowdhury MI, Faruque SM, Salam MA, Ahmed T, Begum YA, et al. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. J Infect Dis 2005; 192:573-9. (Pubitemid 41099305)
174. Qadri F, Chowdhury MI, Faruque SM, Salam MA, Ahmed T, Begum YA, et al. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine 2007; 25:231-8. (Pubitemid 44856084)
175. Garcia L, Jidy MD, Garcia H, Rodriguez BL, Fernandez R, Ano G, et al. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers. Infect Immun 2005; 73:3018-24.
176. Roland KL, Cloninger C, Kochi SK, Thomas LJ, Tinge SA, Rouskey C, et al. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli. Vaccine 2007; 25:8574-84. (Pubitemid 350192041)
177. Turner AK, Terry TD, Sack DA, Londono-Arcila P, Darsley MJ. Construction and characterization of genetically defined aro omp mutants of enterotoxigenic Escherichia coli and preliminary studies of safety and immunogenicity in humans. Infect Immun 2001; 69:4969-79.
178. McKenzie R, Darsley M, Thomas N, Randall R, Carpenter C, Forbes E, et al. A double-blind, placebo-controlled trial to evaluate the efficacy of PTL-003, an attenuated enterotoxigenic E. coli (ETEC) vaccine strain, in protecting against challenge with virulent ETEC. Vaccine 2008; 26:4731-9.
179. Turner AK, Beavis JC, Stephens JC, Greenwood J, Gewert C, Thomas N, et al. Construction and phase I clinical evaluation of the safety and immunogenicity of a candidate enterotoxigenic Escherichia coli vaccine strain expressing colonization factor antigen CFA/I. Infect Immun 2006; 74:1062-71.
180. Benevolo-de-Andrade TC, Monteiro-Maia R, Cosgrove C, Castello-Branco LR. BCG Moreau Rio de Janeiro: an oral vaccine against tuberculosis - review. Mem Inst Oswaldo Cruz 2005; 100:459-65.
181. Badell E, Nicolle F, Clark S, Majlessi L, Boudou F, Martino A, et al. Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFNgamma producing T-cells. Vaccine 2009; 27:28-37.
182. Cross ML, Lambeth MR, Aldwell FE. Murine immune responses to oral BCG immunization in the presence or absence of prior BCG sensitization. Immunol Cell Biol 88:224-7.
183. Clark S, Cross ML, Smith A, Court P, Vipond J, Nadian A, et al. Assessment of different formulations of oral Mycobacterium bovis Bacille Calmette-Guerin (BCG) vaccine in rodent models for immunogenicity and protection against aerosol challenge with M. bovis. Vaccine 2008; 26:5791-7.
184. Hall LJ, Clare S, Pickard D, Clark SO, Kelly DL, El Ghany MA, et al. Characterisation of a live Salmonella vaccine stably expressing the Mycobacterium tuberculosis Ag85B-ESAT6 fusion protein. Vaccine 2010; 27:6894-904.
185. Cosgrove CA, Castello-Branco LR, Hussell T, Sexton A, Giemza R, Phillips R, et al. Boosting of cellular immunity against Mycobacterium tuberculosis and modulation of skin cytokine responses in healthy human volunteers by Mycobacterium bovis BCG substrain Moreau Rio de Janeiro oral vaccine. Infect Immun 2006; 74:2449-52.
186. Kotloff KL, Simon JK, Pasetti MF, Sztein MB, Wooden SL, Livio S, Nataro JP, et al. Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media. Hum Vaccin 2007; 3:268-75.
187. Katz DE, Coster TS, Wolf MK, Trespalacios FC, Cohen D, Robins G, et al. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect Immun 2004; 72:923-30.
188. World Health Organization. Future needs and directions for Shigella vaccines. Wkly Epidemiol Rec 2006; 81:51-8.
189. Launay O, Sadorge C, Jolly N, Poirier B, Bechet S, van der Vliet D, et al. Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial. Vaccine 2009; 27:1184-91.
190. Kotloff KL, Taylor DN, Sztein MB, Wasserman SS, Losonsky GA, Nataro JP, et al. Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infect Immun 2002; 70:2016-21.
191. Orr N, Katz DE, Atsmon J, Radu P, Yavzori M, Halperin T, et al. Community-based safety, immunogenicity and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers. Infect Immun 2005; 73:8027-32.
192. Venkatesan MM, Hartman AB, Newland JW, Ivanova VS, Hale TL, McDonough M, et al. Construction, characterization and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine. Infect Immun 2002; 70:2950-8.
193. McKenzie R, Venkatesan MM, Wolf MK, Islam D, Grahek S, Jones AM, et al. Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate. Vaccine 2008; 26:3291-6.
194. Ranallo RT, Thakkar S, Chen Q, Venkatesan MM. Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain. Vaccine 2007; 25:2269-78.
195. Barnoy S, Jeong KI, Helm RF, Suvarnapunya AE, Ranallo RT, Tzipori S, et al. Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity. Vaccine 2010; 28:1642-54.
196. Fraser A, Goldberg E, Acosta CJ, Paul M, Leibovici L. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev 2007; 001261.
197. Levine MM, Ferreccio C, Black RE, Lagos R, San Martin O, Blackwelder WC. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clin Infect Dis 2007; 45:24-8.
198. Sztein MB. Cell-mediated immunity and antibody responses elicited by attenuated Salmonella enterica Serovar Typhi strains used as live oral vaccines in humans. Clin Infect Dis 2007; 45:15-9.
199. + T cells with predominant Vbeta repertoires. Infect Immun 2005; 73:3521-30.
200. Tacket CO, Pasetti MF, Sztein MB, Livio S, Levine MM. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide. J Infect Dis 2004; 190:565-70. (Pubitemid 38982097)
201. Hohmann EL, Oletta CA, Killeen KP, Miller SI. phoP/ phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J Infect Dis 1996; 173:1408-14.
202. Lyon CE, Sadigh KS, Carmolli MP, Harro C, Sheldon E, Lindow JC, et al. In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 x 10(10) colony-forming units. Vaccine 2010; 28:3602-8.
203. Khan S, Chatfield S, Stratford R, Bedwell J, Bentley M, Sulsh S, et al. Ability of SPI2 mutant of S. typhi to effectively induce antibody responses to the mucosal antigen enterotoxigenic E. coli heat labile toxin B subunit after oral delivery to humans. Vaccine 2007; 25:4175-82.
204. Bumann D, Behre C, Behre K, Herz S, Gewecke B, Gessner JE, et al. Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers. Vaccine 2010; 28:707-13.
205. Florence AT. The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. Pharm Res 1997; 14:259-66.
206. Katz DE, DeLorimier AJ, Wolf MK, Hall ER, Cassels FJ, van Hamont JE, et al. Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen. Vaccine 2003; 21:341-6.
207. Brayden DJ. Oral vaccination in man using antigens in particles: current status. Eur J Pharm Sci 2001; 14:183-9.
208. Baumann U, Gocke K, Gewecke B, Freihorst J, von Specht BU. Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study. Respir Res 2007; 8:57.
209. Sorichter S, Baumann U, Baumgart A, Walterspacher S, von Specht BU. Immune responses in the airways by nasal vaccination with systemic boosting against Pseudomonas aeruginosa in chronic lung disease. Vaccine 2009; 27:2755-9.
210. Fujihashi K, Koga T, van Ginkel FW, Hagiwara Y, McGhee JR. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 2002; 20:2431-8. (Pubitemid 34615580)
211. Belshe R, Lee MS, Walker RE, Stoddard J, Mendelman PM. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev Vaccines 2004; 3:643-54.
212. Belshe RB, Nichol KL, Black SB, Shinefield H, Cordova J, Walker R, et al. Safety, efficacy and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. Clin Infect Dis 2004; 39:920-7.
213. Buonagurio DA, Bechert TM, Yang CF, Shutyak L, D'Arco GA, Kazachkov Y, et al. Genetic stability of live, cold-adapted influenza virus components of the FluMist/CAIV-T vaccine throughout the manufacturing process. Vaccine 2006; 24:2151-60.
214. Neumann G, Fujii K, Kino Y, Kawaoka Y. An improved reverse genetics system for influenza A virus generation and its implications for vaccine production. Proc Natl Acad Sci USA 2005; 102:16825-9.
215. Centres for Disease Control and Prevention (CDC). Flu activity and surveillance. Available at http://www. cdc.gov/flu/weekly/fluactivity.htm.
216. Wacheck V, Egorov A, Groiss F, Pfeiffer A, Fuereder T, Hoeflmayer D, et al. A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. J Infect Dis 2010; 201:354-62.
217. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89:422-34.
218. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969; 89:405-21.
219. Murphy BR, Collins PL. Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. J Clin Invest 2002; 110:21-7.
220. Wright PF, Karron RA, Belshe RB, Shi JR, Randolph VB, Collins PL, et al. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine 2007; 25:7372-8.
221. Tang RS, Spaete RR, Thompson MW, MacPhail M, Guzzetta JM, Ryan PC, et al. Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity and enhanced disease and initial clinical testing in healthy adults. Vaccine 2008; 26:6373-82.
222. Gomez M, Mufson MA, Dubovsky F, Knightly C, Zeng W, Losonsky G. Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children. Pediatr Infect Dis J 2009; 28:655-8.
223. Karron RA, Wright PF, Newman FK, Makhene M, Thompson J, Samorodin R, et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J Infect Dis 1995; 172:1445-50.
224. Karron RA, Belshe RB, Wright PF, Thumar B, Burns B, Newman F, et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J 2003; 22:394-405.
225. Belshe RB, Newman FK, Tsai TF, Karron RA, Reisinger K, Roberton D, et al. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old. J Infect Dis 2004; 189:462-70.
226. Madhi SA, Cutland C, Zhu Y, Hackell JG, Newman F, Blackburn N, et al. Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers. Vaccine 2006; 24:2432-9.
227. Bartlett EJ, Castano A, Surman SR, Collins PL, Skiadopoulos MH, Murphy BR. Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes. Virol J 2007; 4:67.
228. Samdal HH, Bakke H, Oftung F, Holst J, Haugen IL, Korsvold GE, et al. A non-living nasal influenza vaccine can induce major humoral and cellular immune responses in humans without the need for adjuvants. Hum Vaccin 2005; 1:85-90.
229. Huckriede A, Bungener L, Stegmann T, Daemen T, Medema J, Palache AM, et al. The virosome concept for influenza vaccines. Vaccine 2005; 23:26-38.
230. Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. Methods 2006; 40:60-5.
231. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK. Humoral, mucosal and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol 2003; 108:241-7.
232. Langley JM, Halperin SA, McNeil S, Smith B, Jones T, Burt D, et al. Safety and immunogenicity of a Proteosome-trivalent inactivated influenza vaccine, given nasally to healthy adults. Vaccine 2006; 24:1601-8.
233. Treanor J, Nolan C, O'Brien D, Burt D, Lowell G, Linden J, et al. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine 2006; 24:254-62.
234. Fries LF, Montemarano AD, Mallett CP, Taylor DN, Hale TL, Lowell GH. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect Immun 2001; 69:4545-53.
235. Halperin SA, Smith B, Clarke K, Treanor J, Mabrouk T, Germain M. Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults. Hum Vaccin 2005; 1:37-42.
236. Betancourt AA, Delgado CA, Estevez ZC, Martinez JC, Rios GV, Aureoles-Rosello SR, et al. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int J Infect Dis 2007; 11:394-401.
237. Childers NK, Li F, Dasanayake AP, Li Y, Kirk K, Michalek SM. Immune response in humans to a nasal boost with Streptococcus mutans antigens. Oral Microbiol Immunol 2006; 21:309-13.
238. Hiremath GS, Omer SB. A meta-analysis of studies comparing the respiratory route with the subcutaneous route of measles vaccine administration. Hum Vaccin 2005; 1:30-6.
239. Low N, Kraemer S, Schneider M, Restrepo AM. Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis. Vaccine 2008; 26:383-98.
240. Bennett JV, Fernandez de Castro J, Poblete RM, Alcantara ML, Diaz EG, Angeles MA, et al. A new, rapid and promising approach to aerosol immunization: inflatable bags and valved masks. Vaccine 2009; 27:4571-5.
241. Diaz-Ortega JL, Bennett JV, Castaneda D, Vieyra JR, Valdespino-Gomez JL, de Castro JF. Successful seroresponses to measles and rubella following aerosolized Triviraten vaccine, but poor response to aerosolized mumps (Rubini) component: comparisons with injected MMR. Vaccine 2010; 28:692-8.
242. Wong-Chew RM, Islas-Romero R, Garcia-Garcia Mde L, Beeler JA, Audet S, Santos-Preciado JI, et al. Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children. Vaccine 2006; 24:683-90.
243. Proceedings of the Eighth Global Vaccine Research Forum and Parallel Satellite Symposia. Institut Pasteur. Paris, France 2008; 2.
244. Nardelli-Haefliger D, Lurati F, Wirthner D, Spertini F, Schiller JT, Lowy DR, et al. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine 2005; 23:3634-41.
245. Pialoux G, Hocini H, Perusat S, Silberman B, Salmon- Ceron D, Slama L, et al. Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/ LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study. Vaccine 2008; 26:2657-66.
246. Wright PF, Mestecky J, McElrath MJ, Keefer MC, Gorse GJ, Goepfert PA, et al. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. J Infect Dis 2004; 189:1221-31.
247. Lindenburg CE, Stolte I, Langendam MW, Miedema F, Williams IG, Colebunders R, et al. Long-term followup: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression. Vaccine 2002; 20:2343-7.
248. Hopkins WJ, Elkahwaji J, Beierle LM, Leverson GE, Uehling DT. Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial. J Urol 2007; 177:1349-53.
249. Sharma R, Schumacher U, Adam E. Lectin histochemistry reveals the appearance of M-cells in Peyer's patches of SCID mice after syngeneic normal bone marrow transplantation. J Histochem Cytochem 1998; 46:143-8.
250. Manocha M, Pal PC, Chitralekha KT, Thomas BE, Tripathi V, Gupta SD, et al. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target. Vaccine 2005; 23:5599-617.
251. Foster N, Clark MA, Jepson MA, Hirst BH. Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo. Vaccine 1998; 16:536-41.
252. Chionh YT, Wee JL, Every AL, Ng GZ, Sutton P. M-cell targeting of whole killed bacteria induces protective immunity against gastrointestinal pathogens. Infect Immun 2009; 77:2962-70.
253. Pielage JF, Cichon C, Greune L, Hirashima M, Kucharzik T, Schmidt MA. Reversible differentiation of Caco-2 cells reveals galectin-9 as a surface marker molecule for human follicle-associated epithelia and M cell-like cells. Int J Biochem Cell Biol 2007; 39:1886-901.
254. Hirabayashi J, Hashidate T, Arata Y, Nishi N, Nakamura T, Hirashima M, et al. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta 2002; 1572:232-54.
255. Girardin SE, Sansonetti PJ, Philpott DJ. Intracellular vs extracellular recognition of pathogens - common concepts in mammals and flies. Trends Microbiol 2002; 10:193-9.
256. Tyrer P, Foxwell AR, Cripps AW, Apicella MA, Kyd JM. Microbial pattern recognition receptors mediate M-cell uptake of a gram-negative bacterium. Infect Immun 2006; 74:625-31.
257. Akashi S, Saitoh S, Wakabayashi Y, Kikuchi T, Takamura N, Nagai Y, et al. Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14. J Exp Med 2003; 198:1035-42.
258. Swords WE, Buscher BA, Ver Steeg Ii K, Preston A, Nichols WA, Weiser JN, et al. Non-typeable Haemophilus influenzae adhere to and invade human bronchial epithelial cells via an interaction of lipo-oligosaccharide with the PAF receptor. Mol Microbiol 2000; 37:13-27.
259. Kaminski RW, Turbyfill KR, Chao C, Ching WM, Oaks EV. Mucosal adjuvanticity of a Shigella invasin complex with dna-based vaccines. Clin Vaccine Immunol 2009; 16:574-86.
260. Turbyfill KR, Hartman AB, Oaks EV. Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine. Infect Immun 2000; 68:6624-32.
261. Clark MA, Hirst BH, Jepson MA. M-cell surface beta1 integrin expression and invasin-mediated targeting of Yersinia pseudotuberculosis to mouse Peyer's patch M cells. Infect Immun 1998; 66:1237-43.
262. Gullberg E, Keita AV, Salim SY, Andersson M, Caldwell KD, Soderholm JD, et al. Identification of cell adhesion molecules in the human follicle-associated epithelium that improve nanoparticle uptake into the Peyer's patches. J Pharmacol Exp Ther 2006; 319:632-9.
263. Tyrer P, Ruth Foxwell A, Kyd J, Harvey M, Sizer P, Cripps A. Validation and quantitation of an in vitro M-cell model. Biochem Biophys Res Commun 2002; 299:377-83.
264. Secott TE, Lin TL, Wu CC. Mycobacterium avium subsp. paratuberculosis fibronectin attachment protein facilitates M-cell targeting and invasion through a fibronectin bridge with host integrins. Infect Immun 2004; 72:3724-32.
265. Van Nhieu GT, Isberg RR. The Yersinia pseudotuberculosis invasin protein and human fibronectin bind to mutually exclusive sites on the alpha5beta1 integrin receptor. J Biol Chem 1991; 266:24367-75.
266. Mason HS, Lam DM, Arntzen CJ. Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci USA 1992; 89:11745-9.
267. Daniell H, Singh ND, Mason H, Streatfield SJ. Plant-made vaccine antigens and biopharmaceuticals. Trends Plant Sci 2009; 14:669-79.
268. Tacket CO. Plant-derived vaccines against diarrheal diseases. Vaccine 2005; 23:1866-9.
269. Thanavala Y, Mahoney M, Pal S, Scott A, Richter L, Natarajan N, et al. Immunogenicity in humans of an edible vaccine for hepatitis B. Proc Natl Acad Sci USA 2005; 102:3378-82.
270. Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ. Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis 2000; 182:302-5.
271. Tacket CO, Pasetti MF, Edelman R, Howard JA, Streatfield S. Immunogenicity of recombinant LT-B delivered orally to humans in transgenic corn. Vaccine 2004; 22:4385-9.
272. Tacket CO. Plant-based vaccines against diarrheal diseases. Trans Am Clin Climatol Assoc 2007; 118:79-87.
273. Nochi T, Takagi H, Yuki Y, Yang L, Masumura T, Mejima M, et al. Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination. Proc Natl Acad Sci USA 2007; 104:10986-91.
274. Landscape Analysis. Trends in vaccine availability and novel vaccine delivery technologies: 2008-2025. In: Organization WH, Ed. Path 2008.
275. Mitragotri S. Immunization without needles. Nat Rev Immunol 2005; 5:905-16.
276. Borges O, Lebre F, Bento D, Borchard G, Junginger HE. Mucosal vaccines: recent progress in understanding the natural barriers. Pharm Res 2010; 27:211-23.
277. Brandtzaeg P. The mucosal immune system and its integration with the mammary glands. J Pediatr 2010; 156:8-15.